iFabrick (IFA) Corporate presentation summary
Event summary combining transcript, slides, and related documents.
Corporate presentation summary
18 Sep, 2026Company overview and business model
Operates a Canadian-listed textile technology platform with 40 years of history, proprietary chemistry IP, and global distribution.
Utilizes a capital-light, asset-light model with manufacturing in 9 countries and three main revenue streams: proprietary chemistry, product design, and major retailer distribution.
Two main divisions: Intelligent Fabric Technologies (IFTNA) as the growth engine and Coconut Grove Intimates as a cash-flow foundation.
Proprietary chemistries like PROTX2Ⓡ and ecoPEL™ are licensed and sold to global brands, driving growth and margin expansion.
Technology and product ecosystem
Offers 18 proprietary, patented or patent-pending textile technologies, including antimicrobial, antiviral, moisture management, water repellency, cooling, UV, and wellness features.
Technologies are integrated at the fiber or fabric level, compatible with existing global manufacturing, requiring no infrastructure buildout.
Finished products include apparel, scrubs, intimates, activewear, underwear, swimwear, footwear, bedding, and home textiles.
Monetizes technology both as chemical/platform sales and higher-value finished goods programs.
Commercial reach and retail execution
Embedded with leading brands and retailers such as Walmart, Target, Costco, Kohl's, Amazon, Macy's, Hudson's Bay, lululemon, The North Face, Under Armour, and Roots.
Converts proprietary technologies and brand relationships into full retail assortments across apparel, scrubs, intimates, and essentials.
Major retail programs in the US and Canada, including Walmart (Joyspun, No Boundaries, Doctor's Choice), Target (Aura scrubs), and Costco.
Owned, licensed, and private label brands include Verzus All, Threads, The Natural, Frontline, Roots, Doctor's Choice, and more.
Latest events from iFabrick
- Record revenue and EBITDA, strong cash, and growth in scrubs and new product launches.IFA
Q2 2026 - Record Q1 revenue of $27.5M, up 288%, driven by new products and retail expansion.IFA
Q1 2026 - Clinically validated textile platform achieves record growth and expands into new markets.IFA
Investor presentation - Record revenue and strong Q1 2026 outlook, with margin recovery expected as tariffs ease.IFA
Q4 2025 - Q3 2025 revenue jumped 111% year-over-year, with margin pressure expected to ease ahead.IFA
Q3 2025 - Record deposits and new market entry drive strong future growth despite margin pressure.IFA
Q2 2025 - Proprietary textile technologies and medical focus drive strong growth and global expansion.IFA
Planet MicroCap Showcase: VEGAS 2025 - Record Q1 revenue achieved, but margin pressure and higher costs reduced earnings.IFA
Q1 2025 - Record revenue and profitability in 2024, with double-digit growth expected in 2025.IFA
Q4 2024